Skip to main content
. 2020 Jun 18;18(6):e06110. doi: 10.2903/j.efsa.2020.6110
Codea Commodity

Existing

EU MRLb

(mg/kg)

Proposed

EU MRL

(mg/kg)

Comment/justification
Enforcement residue definition: Lambda‐cyhalothrin (includes gamma‐cyhalothrin) (sum of R,S‐ and S,R‐isomers)(F)
0810000 Seed spices

0.01*

(ft)

0.3

(ft)

Further risk management considerations necessary

The submitted data are sufficient to derive an MRL proposal for the intended NEU use

Risk for consumers unlikely

A risk management decision is required whether it is appropriate to take over the MRL in the MRL legislation, despite the lack of toxicological data for certain degradation products (compounds Ia, IV and gamma lactone) observed in standard hydrolysis studies representative for sterilisation conditions

0820000, except 0820040 Fruit spices, except cardamom

0.03

(ft)

0.3

(ft)

Further risk management considerations necessary

The submitted data are sufficient to derive an MRL proposal by extrapolation from spice seeds for the intended NEU use

Risk for consumers unlikely

A risk management decision is required whether it is appropriate to take over the MRL in the MRL legislation, despite the lack of toxicological data for certain degradation products (compounds Ia, IV and gamma lactone) observed in standard hydrolysis studies representative for sterilisation conditions

0820040 Cardamon

2

(ft)

2

(ft)

(No change required)

The submitted data are sufficient to derive an MRL proposal of 0.3 mg/kg by extrapolation from spice seeds for the intended NEU use, which is lower than the existing tentative MRL

MRL: maximum residue level; NEU: northern Europe.

*

Indicates that the MRL is set at the limit of analytical quantification (LOQ).

a

Commodity code number according to Annex I of Regulation (EC) No 396/2005.

b

Existing EU MRL and corresponding footnote on confirmatory data.

(F): Fat soluble.

(ft): The European Food Safety Authority identified some information on certain metabolites (compounds Ia, IV and gamma‐lactone) formed under sterilisation conditions as unavailable. When reviewing the MRL, the Commission will take into account the information referred to in the first sentence, if it is submitted by 6 July 2020, or, if that information is not submitted by that date, the lack of it.